MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Blood

• Publication date

  2003-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V101.6.2368PMID 12609962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

  2002cited by this paper
• Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.

  2002cited by this paper
• High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

  2002cited by this paper
• The Leukemia-Lymphoma Cell Line Facts Book

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

  2002cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Molecular genetic analysis and biochemical characterization of mammalian P-glycoproteins involved in multidrug resistance.

  2001cited by this paper
• Roots of Clinical Resistance to STI-571 Cancer Therapy

  2001cited by this paper
• Roots of clinical resistance to STI-571 cancer therapy.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia.

  2001cited by this paper
• Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

  2000cited by this paper
• STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.

  2000cited by this paper
• Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

  2000cited by this paper
• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

  2000cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• Reversal of multidrug resistance in hematological malignancies.

  1999cited by this paper
• Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents

  1999cited by this paper
• Multidrug resistance protein expression in chronic myeloid leukemia

  1999cited by this paper
• Prognostic value of P-glycoprotein and leukocyte differentiation antigens in chronic myeloid leukemia.

  1998cited by this paper
• The Molecular Biology of Chronic Myeloid Leukaemia

  1998cited by this paper
• Longitudinal Evaluation of Salivary Cortisol Levels in Full-Term and Preterm Neonates

  1998cited by this paper
• Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.

  1998cited by this paper
• Multidrug-resistant gene expression in small-cell lung cancer.

  1997cited by this paper
• Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations.

  1997cited by this paper
• Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.

  1996cited by this paper
• The molecular biology of chronic myeloid leukaemia.

  1996cited by this paper
• The molecular biology of chronic myeloid leukaemia.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.

  1995cited by this paper
• A temperature sensitive p210 BCR‐ABL mutant defines the primary consequences of BCR‐ABL tyrosine kinase expression in growth factor dependent cells.

  1994cited by this paper
• Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells.

  1993cited by this paper
• Clinical significance of P-glycoprotein in multidrug resistance malignancies

  1993cited by this paper
• Clinical significance of P-glycoprotein in multidrug resistance malignancies.

  1993cited by this paper
• Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression.

  1993cited by this paper
• Clinical significance of P-glycoprotein in multidrug resistance malignancies [editorial] [see comments]

  1993cited by this paper
• Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.

  1991cited by this paper
• Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.

  1988cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

  1976cited by this paper
• Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells.

  1973cited by this paper

• Drug resistance in chronic myeloid leukemia: the involvement of Galectin-1 and Galectin-3

  2026cites this paper
• Allosteric Inhibition of P-Glycoprotein-Mediated Efflux by DMH1

  2025cites this paper
• Computationally Driven Discovery of a BCR-ABL1 Kinase Inhibitor with Activity in Multidrug-Resistant Chronic Myeloid Leukemia

  2024cites this paper
• Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells

  2024cites this paper
• The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells.

  2024cites this paper
• Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia

  2024cites this paper
• Tyrosine Kinase Inhibitors in Cancers: Treatment optimization - Part II.

  2024cites this paper
• Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.

  2024cites this paper
• Multimodal Mass Spectrometry Imaging of an Osteosarcoma Multicellular Tumour Spheroid Model to Investigate Drug-Induced Response

  2024cites this paper
• AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects

  2023cites this paper
• Minerals, serum metabolites, hormones, and bovine reproduction: a review

  2023cites this paper
• Targeting BCR-ABL1-positive leukaemias: a review article

  2023cites this paper
• Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia

  2023cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system

  2022cites this paper
• Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery

  2022cites this paper
• The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia

  2022cites this paper
• Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia

  2022cites this paper
• OTT_A_289306 103..116

  2022cites this paper
• Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells

  2022cites this paper
• The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.

  2022cites this paper
• Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

  2022cites this paper
• The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation

  2022cites this paper
• Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia

  2022cites this paper
• Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review

  2022cites this paper
• Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia

  2022cites this paper
• A targeted and redox/pH-responsive chitosan oligosaccharide derivatives based nanohybrids for overcoming multidrug resistance of breast cancer cells.

  2021cites this paper
• Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia

  2021cites this paper
• Lactose-binding lectin from Vatairea macrocarpa seeds induces in vivo angiogenesis via VEGF and TNF-ɑ expression and modulates in vitro doxorubicin-induced genotoxicity.

  2021cites this paper
• A Novel Anticancer Stem Cell Compound Derived from Pleuromutilin Induced Necroptosis of Melanoma Cells.

  2021cites this paper
• Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents

  2021cites this paper
• The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML

  2021cites this paper
• A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia

  2021cites this paper
• Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells

  2021cites this paper
• Hesperidin and its aglycone hesperetin in breast cancer therapy: A review of recent developments and future prospects

  2021cites this paper
• MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis

  2021cites this paper
• Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response

  2020cites this paper
• Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients

  2020cites this paper
• Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

  2020cites this paper
• Overexpression of P‐glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients

  2020cites this paper
• Targeting MDR‐1 gene expression, BAX/BCL2, caspase‐3, and Ki‐67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity

  2020cites this paper
• Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs

  2020cites this paper
• Discovery of ABCG2/VEGFR2 Dual-Target Inhibitor With Anti-Drug Resistance Activity Based on the ATP Binding Site

  2020cites this paper
• Declaration of Bcr-Abl1 independence

  2020cites this paper
• CDK5/CAMK2-DRP1-AMPK-Mediated Mitochondrial Fission is Required for Imatinib Resistance of CML Cells

  2020cites this paper
• Downregulation of MDR 1 gene contributes to tyrosine kinase inhibitor induce apoptosis and reduction in tumor metastasis: A gravity to space investigation.

  2020cites this paper
• Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice

  2020cites this paper
• Mutation Analysis of ABL1 Gene and its Relation to the Achievement of Major Molecular Response in Indonesian Chronic Myeloid Leukemia Patients

  2020cites this paper
• The Role of JAK2 Gene in Imatinib-Resistant Chronic Myeloid Leukemia: A Review

  2020cites this paper
• Complexes of Co(II), Cu(II) and Ni(II) with Antineoplastic Agent Imatinib Mesylate: Synthesis, Characterization and Biological Activity

  2019cites this paper
• Resistance to Anti-Cancer Therapeutics

  2019cites this paper
• Chronic myelogenous leukemia Chronic myeloid leukemia stem cells

  2019cites this paper
• Pharmacogenes (PGx-genes): Current understanding and future directions.

  2019cites this paper
• Multiple Molecular Mechanisms Contribute Towards In Vitro Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia

  2019cites this paper
• Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia

  2019cites this paper
• Multi-targeting Anticancer Agents: Rational Approaches, Synthetic Routes and Structure Activity Relationship.

  2019cites this paper
• Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib

  2019cites this paper
• Longer Hydroxyurea Administration Prior to Imatinib Mesylate is Risk Factor for Unsuccessful Major Molecular Response in Chronic-Phase Chronic Myeloid Leukemia: Possibility of P-Glycoprotein Role

  2019cites this paper
• Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type

  2019cites this paper
• Chemotherapy and Inflammatory Cytokine Signalling in Cancer Cells and the Tumour Microenvironment.

  2019cites this paper
• Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia

  2019cites this paper
• Chronic myeloid leukemia stem cells

  2019cites this paper
• T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system

  2018cites this paper
• Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo

  2018cites this paper
• Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer.

  2018cites this paper
• Diagnosis and Treatment of Chronic Myeloid Leukemia

  2018cites this paper
• Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia

  2018cites this paper
• Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.

  2018cites this paper
• Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.

  2018cites this paper
• CANCER THERAPY

  2018cites this paper
• Chronic Myeloid Leukemia (CML)

  2018cites this paper
• Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines

  2018cites this paper
• Alkynylnicotinamide‐Based Compounds as ABL1 Inhibitors with Potent Activities against Drug‐Resistant CML Harboring ABL1(T315I) Mutant Kinase

  2018cites this paper
• Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method

  2018cites this paper
• Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.

  2018cites this paper
• Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

  2018cites this paper
• Comparative Pharmacology of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia

  2018cites this paper
• A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line.

  2017cites this paper
• Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels.

  2017cites this paper
• ABCB1 genetic variants in leukemias: current insights into treatment outcomes

  2017cites this paper
• Strategies in the Era of Personalised Medicine

  2017influential citation
• Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance

  2017cites this paper
• The Response of Cancer Cell Populations to Therapies

  2017cites this paper
• Monitoring plasma imatinib level to improve results of therapy of chronic myeloid leukosis

  2017cites this paper
• Gastrointestinal Hormone Cholecystokinin Increases P-Glycoprotein Membrane Localization and Transport Activity in Caco-2 Cells.

  2017cites this paper
• The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

  2017cites this paper
• lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells

  2017cites this paper
• UNIVERSITY OF NAPLES "FEDERICO II" Doctorate School in Advanced Medical and Surgical Therapies XXIX Cycle

  2017cites this paper
• Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein

  2017cites this paper
• Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.

  2017cites this paper
• Molecular techniques for the personalised management of patients with chronic myeloid leukaemia

  2017cites this paper
• Pharmacokinetic‐Guided Dosing of New Oral Cancer Agents

  2017cites this paper
• A stronger reversal effect of the combination of dasatinib and menadione on P-gp-mediated multidrug resistance in human leukemia K562/Adr cell line

  2017cites this paper
• Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia

  2017cites this paper
• Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

  2017cites this paper
• Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib

  2016cites this paper
• Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.

  2016cites this paper
• Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy

  2016cites this paper
• Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells

  2016cites this paper
• Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors

  2016cites this paper